Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
 
Register now or login to post to this thread.
  • Page:
  • 1
  • 2

MyLotus beginning to blossom (CPT)     

kimoldfield - 08 Aug 2016 11:38

Chart.aspx?Provider=EODIntra&Code=CPT&Si

Frontier Resources (AIM:FRI), agreed to acquire Concepta Diagnostics Limited (“Concepta”), a pioneering UK healthcare company established in 2013, that has developed proprietary products and a platform, which targets the personalised mobile health market with a primary focus on women’s fertility and specifically unexplained infertility. SPARK Advisory Partners is acting as Nominated Adviser and Financial Adviser to the Company with Beaufort Securities as Broker.

This acquisition has been completed, FRI is now CPT

From RNS 26.7.2016:- "Mercia Technologies PLC (AIM: MERC), which is focused on the creation, funding and scaling of innovative businesses with high growth potential from the UK regions, is delighted to announce the successful admission of the enlarged share capital of Concepta PLC ("Concepta", AIM: CPT), one of its direct portfolio companies formerly named Concepta Diagnostics Ltd, to trading on AIM at 8.00am today."


http://www.conceptaplc.com/concepta/about-us
Concepta's flagship product MyLotus has a unique offering, allowing women to see YES / NO results as well as their actual and personal level of factors that can have a direct influence on fertility – MyLotus is the only home-test on the market that currently offers this.

MyLotus has the ability to quantify personal hormone levels enabling the identification of the fertile period for a large number of women, especially for the significant amount of women whose hCG and LH levels vary from mean levels.

kimoldfield - 30 Aug 2016 16:49 - 12 of 35

Nooooo, as little as that?! :o)

kimoldfield - 30 Aug 2016 16:50 - 13 of 35

Which one?

dreamcatcher - 30 Aug 2016 16:55 - 14 of 35

Well done all. :-))

Bullshare - 31 Aug 2016 14:03 - 15 of 35

Its blue again today, well done kimoldfield, when shall we sell ;-0)

dreamcatcher - 31 Aug 2016 16:31 - 16 of 35

When kim does.lol

kimoldfield - 31 Aug 2016 17:25 - 17 of 35

Already have! :o)

dreamcatcher - 31 Aug 2016 17:27 - 18 of 35

They will rocket now. :-))

kimoldfield - 31 Aug 2016 17:28 - 19 of 35

Well, not entirely, sold enough for a profit and a nice holding of free shares! I will be buying again on any dip in price; of course it may not happen if they are going to £1 by Xmas!

kimoldfield - 31 Aug 2016 17:30 - 20 of 35

Yes DC, if they do it will be your fault! :o)

dreamcatcher - 31 Aug 2016 17:30 - 21 of 35

Beware kim still holds. lol

kimoldfield - 31 Aug 2016 17:31 - 22 of 35

Lol! You have been warned! :o)

dreamcatcher - 31 Aug 2016 17:37 - 23 of 35

Well done,

Bullshare - 01 Sep 2016 09:58 - 24 of 35

I'm still in but getting twitchy!

Bullshare - 01 Sep 2016 10:28 - 25 of 35

Steve; I have just PM'ed you via MoneyAM.

M

kimoldfield - 01 Sep 2016 11:10 - 26 of 35

Thanks Mike, I have replied!

SP possibly at top for this week!

Bullshare - 12 Sep 2016 09:32 - 27 of 35

Sold out today, got 18.95p. Steve, again thanks for this one:-)

kimoldfield - 12 Sep 2016 11:04 - 28 of 35

My pleasure Mike! Keep an eye on it, more to come at some point.

Bullshare - 12 Sep 2016 12:41 - 29 of 35

I will probably let it retrace a bit then get back in.

kimoldfield - 26 Sep 2016 08:16 - 30 of 35

RNS Number : 7527K
Concepta PLC
26 September 2016


Concepta plc ("Concepta" or the "Company")
Chinese Manufacturing Agreement Signed with Shijiazhuang Huanzhong Biotech Limited 


Concepta plc (AIM:CPT), the UK healthcare company targeting the personalised mobile health market with a primary focus on women's fertility, announces that it has signed a Manufacturing Agreement ('the Agreement') with Shijiazhuang Huanzhong Biotech Limited ('HZ Biotech'), a leading Chinese manufacturer with operations in Shijiazhuang, to assemble and package Concepta's 'My Lotus' fertility product. This Agreement is in line with the Company's strategy as it builds towards the launch of its My Lotus product for unexplained infertility* into China in H2 2016.

Under the terms of the Agreement, HZ Biotech will exclusively assemble and package Concepta produced components (including bulk tests and electronic meters), to produce Concepta's My Lotus product to specification for the Chinese market. HZ will utilise its manufacturing site and processes, adhering to locally applicable laws and Chinese regulatory requirements. In addition to assembling the final My Lotus product, HZ Biotech will be the sole purchaser of Concepta's My Lotus product and help facilitate its launch to the Chinese market and include post-market surveillance. Concepta will also look to work with a network of distributors in China to help achieve maximum market penetration in China and will update the market on these developments in due course.

Concepta's MyLotus is the only consumer product which allows both quantitative and qualitative measurements of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems. Competitor products currently only allow qualitative measurement and are based on the 'average woman'.

Commenting on the Agreement, Erik Henau, Concepta CEO said: "I am delighted to announce this agreement with leading Chinese manufacturer HZ Biotech, which marks a significant step for Concepta towards the launch of our 'My Lotus' fertility product into China in 2016. With regulatory approvals already in place in China, the Chinese market represents a highly attractive initial launch market for Concepta. An estimated 4 million women in China each year discover that they have unexplained infertility. The sheer scale of the target market, combined with a growing Chinese middle class for whom our My Lotus product is affordable and recent regulatory changes regarding the one-child policy, all create the conditions for an exceptional market opportunity. As such annual revenue potential for this target market is expected to be worth £250m per annum.

"We look forward to updating the market on our progress with HZ Biotech as we roll out our flagship fertility product in our first international market with the UK and Europe targeted for 2017."

kimoldfield - 09 Jan 2017 13:44 - 31 of 35

Progress is slow but at least it is progress!

Concepta achieves ISO13485 accreditation for its myLotus fertility product ahead of targeted commercial launch in the UK and Europe in H2 2017

Concepta plc (AIM:CPT), the UK healthcare company targeting the personalised mobile health market with a primary focus on women's fertility, is pleased to announce that it has achieved ISO13485 accreditation, a key step in attaining its CE marking for its 'myLotus' product for unexplained infertility*, ahead of a commercial launch in the UK and Europe in H2 2017.

The ISO13485 certification is an endorsement of the Quality Management System (QMS) that underpins the Company's position as a manufacturer of medical devices. The accreditation is recognised on an international scale and is a critical part of gaining regulatory approval for Concepta's myLotus to be sold in the European Union.

Commenting on the agreement, Erik Henau, CEO of Concepta said: "This is a proud moment for the Concepta team and importantly a crucial development towards the launch of our flagship myLotus fertility product into the UK and European markets, where the potential market opportunity is circa £350 million.

"It cannot be underestimated how much work goes into documenting the procedures of an entire organisation within a QMS system and ensuring that the procedures are followed to the point that they become a seamless part of everyday operations. It is a strong endorsement of the quality of an organisation at all levels.

"Further to this we are delighted to report that with regulatory approvals and manufacturing agreements already in place in China we remain on track to roll out the myLotus product into the Chinese market in H1 2017."
  • Page:
  • 1
  • 2
Register now or login to post to this thread.